Lilly’s Retevmo Shows 83% Drop in Recurrence Risk for Early‑Stage RET‑Positive Lung Cancer

The LIBRETTO‑432 trial enrolled 151 patients with stage IB–IIIA RET fusion‑positive NSCLC who had completed curative surgery or radiotherapy. Participants were randomized 1:1 to receive either selpercatinib 160 mg twice daily or placebo for up to three years. At a median follow-up of 24 months, the study met its primary endpoint of investigator‑assessed event‑free survival (EFS). In the pre‑specified stage II–IIIA cohort (n=109), the hazard ratio for recurrence or death was 0.17, translating into an 83% risk reduction versus placebo. The 2‑year EFS rate reached 92% on selpercatinib compared with 61% on placebo, and median EFS had not yet been reached in the experimental arm.

These efficacy signals are striking when placed alongside other biomarker‑driven adjuvant successes such as EGFR‑mutated (osimertinib) and ALK‑rearranged (alectinib) NSCLC, where relative risk reductions have hovered around 60–70%. The magnitude of benefit observed with Retevmo suggests that RET fusions, though rarer (<2% of NSCLC), merit the same comprehensive genomic testing at diagnosis. For investors, the data reinforce the commercial relevance of expanding companion‑diagnostic uptake and could drive a surge in test ordering, a prerequisite for market penetration.

From a financial perspective, Lilly’s stock has rallied roughly 30% over the past month, outpacing the S&P 500 by more than 23 percentage points. The market appears to be pricing in the potential revenue uplift from an expanded label. Assuming a conservative U.S. prevalence of 1.5% among early‑stage NSCLC patients (approximately 15,000 new cases annually), and a projected five‑year uptake of 40%, selpercatinib could generate $300–$350 million in incremental sales in the United States alone, not counting international markets where similar regulatory submissions are expected.

Safety remains a key consideration. The trial confirmed known class effects: grade 3 or higher elevations in liver enzymes occurred in 17–19% of patients on selpercatinib versus ≤3% on placebo, and hypertension was observed in roughly one‑third of participants. While manageable with dose adjustments, these adverse events could affect patient adherence and may require additional monitoring resources in community oncology settings. Investors should watch for any signals from post‑marketing surveillance that might temper the drug’s uptake.

Regulatory momentum is likely to be swift. Lilly has indicated plans to file global submissions based on LIBRETTO‑432 data, and the FDA’s recent track record of granting accelerated approvals for targeted adjuvant therapies suggests a favorable timeline. An approval could also open the door for combination strategies—such as pairing selpercatinib with immunotherapy in high‑risk patients—potentially extending the product’s lifecycle.

In summary, the LIBRETTO‑432 results position Retevmo as a potential new standard of care for early‑stage RET‑positive NSCLC, delivering a dramatic reduction in recurrence risk. For shareholders, this translates into a near‑term catalyst that could lift Lilly’s oncology revenue outlook, while also underscoring the importance of broad genomic testing to capture the eligible patient pool.